Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy

Transplantation

Volumn 74, Issue 1, 2002, Pages 22-27

  Wu, Tao ^a   Levay Young, Brett ^a   Heuss, Neal ^a   Sozen, Hakan ^a   Kirchhof, Nicole ^a   Sutherland, David E R ^a   Hering, Bernhard ^a   Guo, Zhiguang ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; FLUDARABINE PHOSPHATE; RAPAMYCIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW TRANSPLANTATION; CHIMERA; CONDITIONING; CONTROLLED STUDY; FEMALE; GENDER; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; IRRADIATION; LIVING DONOR; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; OBESITY; ORGAN TRANSPLANTATION; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERUM;

EID: 0037099154     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200207150-00005     Document Type: Article

References (33)

1. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
2. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts
3. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen
4. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
5. Mixed chimerism as an approach to transplantation tolerance
6. Mixed chimerism and transplant tolerance
7. The NOD mouse model of type 1 diabetes: As good as it gets?
8. NOD mice have a generalized defect in their response to transplantation tolerance induction
9. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection
10. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice
11. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: Absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice
12. Patterns of hemopoietic reconstitution in nonobese diabetic mice: Dichotomy of allogeneic resistance versus competitive advantage of disease-resistant marrow
13. Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice
14. Assessment of microchimerism in rat liver transplantation by polymerase chain reaction
15. Detection of donor-derived cells by polymerase chain reaction in neonatally tolerant mice: Microchimerism fails to predict tolerance
16. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice
17. Induction of diabetes in NOD↔C57BL/6 embryo aggregation chimeras by cyclophosphamide through preferential depletion of C57BL/6 lymphocytes
18. Protection against diabetes by MHC heterozygosity and reversal by cyclophosphamide
19. NOR/Lt mice: MHC-matched diabetes-resistant control strain for NOD mice
20. Bone marrow transplantation for autoimmune diseases
21. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
22. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia
23. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies
24. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia
25. Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity
26. Severe immunodeficiency in patients treated with fludarabine monophosphate
27. Fludarabine phosphate: A new active agent in hematologic malignancies
28. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines
29. Graft-versus-host disease prevention by rapamycin: Cellular mechanisms
30. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
31. Regulatory T cells: Key controllers of immunologic self-tolerance
32. Regulatory T cells in autoimmunity
33. Certified professionals: CD4(+)CD25(+) suppressor T cells